CompletedNot Applicable

Comparison of Intravenous Labetalol and Intravenous Hydralazine in Severe Preeclampsia

Pakistan132 participantsStarted 2024-05-01

Plain-language summary

Due to limited data regarding preeclampsia from the local population, the debate is still ongoing in the study setting. Hence, the current study was planned to compare the efficacy of labetalol and hydralazine for the treatment of hypertension in patients with severe preeclampsia.

Who can participate

Age range20 Years – 35 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant women * Both primiparous and multiparous women * Aged 20-35 years * Gestational age ≥20weeks (assessed on last menstrual period) * With severe preeclampsia Exclusion Criteria: * Known allergy to hydralazine or labetalol * Deranged liver function tests due to any other cause * Women with pre-existing hypertension systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg * Patients receiving more than one antihypertensive drug since admission * Women with chronic renal failure

What they're measuring

Treatment efficacy

Timeframe: 6 hours

Trial details

NCT IDNCT07572656

SponsorMuhammad Aamir Latif

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-31

View on ClinicalTrials.gov More Preeclampsia trials